Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of Umeclidinium in healthy subjects: Two randomized studies

Clinical Drug Investigation

Volumn 33, Issue 7, 2013, Pages 477-488

  Cahn, Anthony ^a   Tal Singer, Ruth ^b   Pouliquen, Isabelle J ^a   Mehta, Rashmi ^b   Preece, Andrew ^a   Hardes, Kelly ^a   Crater, Glenn ^c   Deans, Amanda ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b GLAXOSMITHKLINE   (United States)

^c GLAXOSMITHKLINE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; PLACEBO; TIOTROPIUM BROMIDE; UMECLIDINIUM;

ADULT; AIRWAY CONDUCTANCE; AREA UNDER THE CURVE; ARTICLE; BRONCHODILATATION; COMMON COLD; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAPHY MONITORING; FEMALE; FORCED EXPIRATORY VOLUME; HOLTER MONITORING; HUMAN; HUMAN EXPERIMENT; INHALER; LUNG FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, INHALATION; ADULT; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PLACEBOS; QUINUCLIDINES; YOUNG ADULT;

EID: 84879834099     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0088-7     Document Type: Article

References (16)

1. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(3):CD008532.
2. Russell R, Anzueto A, Weisman I. Optimizing management of chronic obstructive pulmonary disease in the upcoming decade. Int J Chron Obstruct Pulmon Dis. 2011;6:47-61.
3. Shavelle RM, Paculdo DR, Kush SJ, et al. Life expectancy and years of life lost in chronic obstructive pulmonary disease: findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis. 2009;4:137-48.
4. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. http://www.goldcopd.org/. Accessed 17 Jan 2012.
5. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-303.
6. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-8.
7. Eglen RM, Hegde SS, Watson N. Muscarinic receptor subtypes and smooth muscle function. Pharmacol Rev. 1996;48:531-65.
8. Lainé DI, Luttmann MA, Foley JJ, et al. The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing. Eur Respir J. 2011;38(Suppl. 55):3450.
9. World Medical Association. Declaration of Helsinki - ethical principles for medical research involving human subjects. Version October 1996. http://www.wma.net/en/30publications/10policies/b3/. Accessed 12 Dec 2011.
10. Algate C, et al. Umeclidinium (GSK573719) investigator's brochure. Research Triangle Park: GlaxoSmithKline; 2012 (Data on file).
11. Singh D, Tal-Singer R, Faiferman I, et al. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide; a randomised, double blind, placebo controlled, crossover study in healthy subjects. Brit J Clin Pharm. 2006;61:398-404.
12. Caillaud D, Le Merre C, Martinat Y, et al. A dose-ranging study of tiotropium delivered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients. Int J Chron Obstruct Pulmon Dis. 2007;2:559-65.
13. Kesten S, Jara M, Wentworth C, et al. Pooled clinical trial analysis of tiotropium safety. Chest. 2006;130:1695-703.
14. Salpeter SR. Do inhaled anticholinergics increase or decrease the risk of major cardiovascular events? A synthesis of the available evidence. Drugs. 2009;69:2025-33.
15. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439-50.
16. Agh T, Inotai A, Meszaros A. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 2011;82:328-34.